Pharmacological interventions for smoking cessation: an overview and network meta-analysis.

@article{Cahill2013PharmacologicalIF,
  title={Pharmacological interventions for smoking cessation: an overview and network meta-analysis.},
  author={Kate Cahill and Sarah L Stevens and Rafael Perera and Tim Lancaster},
  journal={The Cochrane database of systematic reviews},
  year={2013},
  volume={5},
  pages={
          CD009329
        }
}
BACKGROUND Smoking is the leading preventable cause of illness and premature death worldwide. Some medications have been proven to help people to quit, with three licensed for this purpose in Europe and the USA: nicotine replacement therapy (NRT), bupropion, and varenicline. Cytisine (a treatment pharmacologically similar to varenicline) is also licensed for use in Russia and some of the former socialist economy countries. Other therapies, including nortriptyline, have also been tested for… Expand
Varenicline and combination nicotine replacement therapy are the most effective pharmacotherapies for treating tobacco use
TLDR
An overview and network meta-analysis of pharmacological interventions for smoking cessation and their comparative efficacies and risks are conducted to help guide treatment, policy and future research. Expand
[Interventions for smoking cessation in 2018].
TLDR
For pharmacological treatments, nicotine replacement therapies as well as bupropion allow to increase 6 month-abstinence rates by more than 80% in comparison with placebo while varenicline prescription doubles success rates in the same conditions. Expand
How do smoking cessation medicines compare with respect to their neuropsychiatric safety? A protocol for a systematic review, network meta-analysis and cost-effectiveness analysis
TLDR
A protocol is presented for a systematic review and network meta-analysis to determine how these smoking cessation medicines compare to each other with respect to their neuropsychiatric safety in adult smokers and to update the evidence regarding the effectiveness and cardiovascular safety of these medicines for use in a cost-effectiveness analysis. Expand
The safety of treatments for tobacco use disorder
TLDR
An overview of current evidence on the safety of first-line pharmacotherapies for the treatment of tobacco use disorder includes nicotine replacement therapy, bupropion sustained-release (SR), and varenicline. Expand
Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis
TLDR
The advantage of varenicline over bupropion SR and TN is greater for women than men, and Clinicians should strongly consider varenICline as the first option treatment for women, while among men, the advantage is less clear. Expand
Antidepressants for smoking cessation.
TLDR
High-certainty evidence that bupropion increased long-term smoking cessation rates was found, and there was insufficient evidence to establish whether participants taking buPropion were more likely to report SAEs compared to those taking placebo, or whether combination bu Propion and nicotine replacement therapy resulted in superior quit rates to NRT alone. Expand
Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies: A Network Meta-Analysis
TLDR
Smoking cessation therapies do not appear to raise the risk of serious cardiovascular disease events, and the use of cessation medications is recommended to increase the likelihood of quitting. Expand
Behavioural interventions for smoking cessation: an overview and network meta-analysis.
TLDR
Behavioural interventions for smoking cessation can increase quit rates, but effectiveness varies on characteristics of the support provided, as analyses from the contributing reviews and from the CNMA showed. Expand
Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence
TLDR
Evidence is strong that varenicline is safe and effective in treating tobacco dependence among people who are at higher risk for neuropsychiatric symptoms and cardiovascular disease and by taking it in combination with other medications, enhancing patient adherence and extending the duration of treatment. Expand
Comparative Effectiveness of Smoking Cessation Medications: A National Prospective Cohort From Taiwan
TLDR
In smoking cessation clinics in Taiwan, varenicline users reported higher abstinence rates than NRT patch users after 6 months, suggesting women and smokers with light/moderate nicotine dependence may also benefit from varenICline in actual clinical practice. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 98 REFERENCES
Effectiveness of smoking cessation therapies: a systematic review and meta-analysis
TLDR
NRT, bupropion and varenicline all provide therapeutic effects in assisting with smoking cessation by conducting a systematic review and meta-analysis and indirect comparisons identify a hierarchy of effectiveness. Expand
Interventions for smoking cessation and reduction in individuals with schizophrenia.
TLDR
Bupropion increases smoking abstinence rates in smokers with schizophrenia, without jeopardizing their mental state and varenicline may also improve smoking cessation rates in schizophrenia, but its possible psychiatric adverse effects cannot be ruled out. Expand
Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials
TLDR
A meta-analysis to compare the treatment effects of 7 approved pharmacologic interventions for smoking cessation found that varenicline was superior to bupropion and all were more efficacious than placebo at promoting smoking abstinence at 6 and 12 months. Expand
Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals
TLDR
A systematic review and meta-analysis aimed to identify all randomized clinical trials (RCTs) of NRT versus inert controls and all observational studies to determine the magnitude of reported adverse effects with NRT and found the use of N RT is associated with a variety of side effects. Expand
Pharmacological interventions for promoting smoking cessation during pregnancy.
TLDR
The primary efficacy outcome was smoking cessation in later pregnancy (in all but one trial, at or around delivery); safety was assessed by 11 outcomes that indicated neonatal and infant well-being; and adherence with trial NRT regimens was low. Expand
Anxiolytics for smoking cessation.
TLDR
None of the trials showed strong evidence of an effect for any of these drugs in helping smokers to quit, but the available evidence does not rule out a possible effect. Expand
Nicotine replacement therapy for smoking cessation.
TLDR
The effectiveness of NRT appears to be largely independent of the intensity of additional support provided to the smoker, and the combination of bupropion and nicotine patch was significantly more effective than nicotine patch alone. Expand
Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease: A Randomized Trial
TLDR
Varenicline was well tolerated and did not increase cardiovascular events or mortality; however, trial size and duration limit definitive conclusions about safety. Expand
Interventions for smokeless tobacco use cessation.
TLDR
Behavioural interventions should be used to help ST users to quit and telephone counselling or an oral examination may increase abstinence rates more than interventions without these components. Expand
Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis
TLDR
Cytisine is an effective treatment for smoking cessation with efficacy comparable to that of other currently licensed treatments, Given its low cost and potential for public health benefit, expedited licensing of cytisine forsmoking cessation is warranted. Expand
...
1
2
3
4
5
...